Patient considerations in metastatic colorectal cancer &amp;ndash; role of panitumumab

Rogers, Jane E.

doi:10.2147/ott.s115430

Cited by 9 publications

(7 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, conformational exposure to this epitope takes precedence over tumorspecific conditions, including EGFR activity imbalance or ECD mutation [36]. Unfortunately, side effects such as skin rash, diarrhea (20%), and so on, were observed in patients who used panitumumab to treat CRC [37]. Therefore, seeking an alternative monoclonal antibody for S492R EGFR is necessary.…”

Section: Discussionmentioning

confidence: 99%

Growth suppression of colorectal cancer expressing S492R EGFR by monoclonal antibody CH12

et al. 2019

View full text Add to dashboard Cite

Colorectal cancer (CRC) is a common malignant tumor in the digestive tract, and 30%-85% of CRCs express epidermal growth factor receptors (EGFRs). Recently, treatments using cetuximab, also named C225, an anti-EGFR monoclonal antibody, for CRC have been demonstrated to cause an S492R mutation in EGFR. However, little is known about the biological function of S492R EGFR. Therefore, we attempted to elucidate its biological function in CRC cells and explore new treatment strategies for this mutant form. Our study indicated that EGFR and S492R EGFR accelerate the growth of CRC cells in vitro and in vivo and monoclonal antibody CH12, which specifically recognizes an EGFR tumor-specific epitope, can bind efficiently to S492R EGFR. Furthermore, mAb CH12 showed significantly stronger growth suppression activities and induced a more potent antibody-dependent cellular cytotoxicity effect on CRC cells bearing S492R EGFR than mAb C225. mAb CH12 obviously suppressed the growth of CRC xenografts with S492R EGFR mutations in vivo. Thus, mAb CH12 may be a promising therapeutic agent in treating patients with CRC bearing an S492R EGFR mutation.

show abstract

Section: Discussionmentioning

confidence: 99%

Growth suppression of colorectal cancer expressing S492R EGFR by monoclonal antibody CH12

et al. 2019

View full text Add to dashboard Cite

show abstract

“…[ [12][13][14][15][16][17][18][19][20][21][22] BRAF Prognosis BRAF mutations indicate a decreased survival rate. [23,24] CEA Diagnosis/Prognosis Widespread use.…”

Section: Krasmentioning

confidence: 99%

“…They found PFS was significantly greater in patients receiving panitumumab with KRAS WT , (HR, 0.45; 95% CI: 0.34 to 0.59) than in the mutant group (HR, 0.99; 95% CI, 0.73 to 1.36) [69]. These practice-changing discoveries have defined restrictions for the use for EGFR-ab therapy to patients with mCRC with wild-type RAS (RAS WT ), sparing up to 60% of patients' futile exposure to toxicity and saving needless cost [22].…”

Section: Krasmentioning

confidence: 99%

Personalized Medicine—Current and Emerging Predictive and Prognostic Biomarkers in Colorectal Cancer

Koulis

Yap

Engel

et al. 2020

Cancers

View full text Add to dashboard Cite

Colorectal cancer (CRC) is the third most common cancer diagnosed worldwide and is heterogeneous both morphologically and molecularly. In an era of personalized medicine, the greatest challenge is to predict individual response to therapy and distinguish patients likely to be cured with surgical resection of tumors and systemic therapy from those resistant or non-responsive to treatment. Patients would avoid futile treatments, including clinical trial regimes and ultimately this would prevent under- and over-treatment and reduce unnecessary adverse side effects. In this review, the potential of specific biomarkers will be explored to address two key questions—1) Can the prognosis of patients that will fare well or poorly be determined beyond currently recognized prognostic indicators? and 2) Can an individual patient’s response to therapy be predicted and those who will most likely benefit from treatment/s be identified? Identifying and validating key prognostic and predictive biomarkers and an understanding of the underlying mechanisms of drug resistance and toxicity in CRC are important steps in order to personalize treatment. This review addresses recent data on biological prognostic and predictive biomarkers in CRC. In addition, patient cohorts most likely to benefit from currently available systemic treatments and/or targeted therapies are discussed in this review.

show abstract

“…The safety profile and its efficacy in treating certain CRC patient populations have led to multiple clinical trials. Figure 1 summarizes the list of CRC treatments reviewed according to their date of application or approval by the Food and Drug Administration (FDA) [7][8][9][10][11][12][13][14][15][16][17]. Despite advances in medical and surgical treatment, the long-term survival rates have not improved much [18].…”

Section: Colorectal Cancer (Crc) and Its Treatmentmentioning

confidence: 99%

“…This is because KRAS activation in KRAS-mutated mCRC patients is independent of upstream EGFR activation [58,59]. A subsequent retrospective study by the FDA on seven randomized trials resulted in the approval of cetuximab and panitumumab only in WT KRAS mCRC patients [3,10]. Previously, KRAS mutation was identified only by mutations in Codon 12 and 13 of Exon 2, which was subsequently found to be insufficient for an accurate prediction of treatment response [60].…”

Section: Kras (Kirsten Rat Sarcoma Viral Oncogene Homolog)mentioning

confidence: 99%

Current Update of Laboratory Molecular Diagnostics Advancement in Management of Colorectal Cancer (CRC)

et al. 2019

View full text Add to dashboard Cite

Colorectal cancer (CRC) continues to be one of the most common cancers globally. The incidence has increased in developing countries in the past few decades, this could be partly attributed to aging populations and unhealthy lifestyles. While the treatment of CRC has seen significant improvement since the advent of target-specific therapies and personalized medicine, CRC is oftentimes detected at late or advanced stages, thereby reducing the efficacy of treatment. Hence, screening for early detection is still the key to combat CRC and to increase overall survival (OS). Considering that the field of medical diagnostics is moving towards molecular diagnostics, CRC can now be effectively screened and diagnosed with high accuracy and sensitivity. Depending on the tumor genotype and genetic profile of the individual, personalized treatments including tyrosine kinase inhibitor therapy and immunotherapy can be administered. Notably, there can be no one single treatment that is effective for all CRC patients due to the variation in tumor genetics, which highlights the importance of molecular diagnostics. This review provides insights on therapeutic modalities, molecular biomarkers, advancement of diagnostic technologies, and current challenges in managing CRC.

show abstract

Patient considerations in metastatic colorectal cancer – role of panitumumab

Cited by 9 publications

References 55 publications

Growth suppression of colorectal cancer expressing S492R EGFR by monoclonal antibody CH12

Growth suppression of colorectal cancer expressing S492R EGFR by monoclonal antibody CH12

Personalized Medicine—Current and Emerging Predictive and Prognostic Biomarkers in Colorectal Cancer

Current Update of Laboratory Molecular Diagnostics Advancement in Management of Colorectal Cancer (CRC)

Contact Info

Product

Resources

About